Recombinant human endostatin (Simcere)

重组人血管内皮抑制素（先声药业）

Report date: 2022/04/18 17:53:10

Base Information

Drug NameRecombinant human endostatin (Simcere)
Drug Alias Namerh-endostatin重组人血管内皮抑制素注射液Endu恩度Endostar +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionNucleolin inhibitorsIntegrin alpha-5/beta-1 antagonistsVascular endothelial growth factor receptor 1 antagonists +[4] 
TargetsIntegrin alpha-5/beta-1Vascular endothelial growth factor receptorGelatinases +[4] 
Therapy Area/IndicationsBrain metastasesAscitesPleural Effusion, Malignant +[8] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2005/09/12
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Simcere Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShandong Xiansheng Zaiming Biopharmaceutical Co LtdJiangsu Simcere Pharmaceutical Co Ltd
Inactive CompaniesPeking UniversitySun Yat-Sen University
Active IndicationsAscitesPleural Effusion, MalignantCarcinoma, Non-Small-Cell Lung
Inactive IndicationsBrain metastasesHead and Neck NeoplasmsEsophageal Neoplasms +[5] 

Other Information

ATC CodeL01
Related LinksN/A